[1]
Nagaich U, Sadhna D. Drug recall: An incubus for pharmaceutical companies and most serious drug recall of history. International journal of pharmaceutical investigation. 2015 Jan-Mar:5(1):13-9. doi: 10.4103/2230-973X.147222. Epub
[PubMed PMID: 25599028]
[2]
Darrow JJ, Avorn J, Kesselheim AS. FDA Approval and Regulation of Pharmaceuticals, 1983-2018. JAMA. 2020 Jan 14:323(2):164-176. doi: 10.1001/jama.2019.20288. Epub
[PubMed PMID: 31935033]
[3]
Tang N, Eisenberg JM, Meyer GS. The roles of government in improving health care quality and safety. Joint Commission journal on quality and safety. 2004 Jan:30(1):47-55
[PubMed PMID: 14738036]
Level 2 (mid-level) evidence
[4]
Kang SY, Sen A, Bai G, Anderson GF. Financial Eligibility Criteria and Medication Coverage for Independent Charity Patient Assistance Programs. JAMA. 2019 Aug 6:322(5):422-429. doi: 10.1001/jama.2019.9943. Epub
[PubMed PMID: 31386135]
[5]
Kang SY, Bai G, Karas L, Anderson GF. Pharmaceutical Industry Support of US Patient Advocacy Organizations: An International Context. American journal of public health. 2019 Apr:109(4):559-561. doi: 10.2105/AJPH.2018.304946. Epub 2019 Feb 21
[PubMed PMID: 30789768]
[6]
Haffajee RL, Frank RG. Generic Drug Policy and Suboxone to Treat Opioid Use Disorder. The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics. 2019 Dec:47(4_suppl):43-53. doi: 10.1177/1073110519898042. Epub
[PubMed PMID: 31955697]
[7]
Warchol JM. Should a Law Governing the Pharmaceutical Market Be Ethically Examined Based on Its Intent or Its Practical Applications? AMA journal of ethics. 2019 Aug 1:21(8):E661-667. doi: 10.1001/amajethics.2019.661. Epub 2019 Aug 1
[PubMed PMID: 31397661]
[8]
Luke MC, Kozak D. Regulating Generic Ophthalmologic Drug Bioequivalence-Envisioning Accessibility for Patients. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics. 2021 Apr:37(3):157-161. doi: 10.1089/jop.2020.0041. Epub 2020 Dec 17
[PubMed PMID: 33332225]
[9]
Epstein RA. The constitutional protection of trade secrets and patents under the Biologics Price Competition and Innovation Act of 2009. Food and drug law journal. 2011:66(3):285-328
[PubMed PMID: 24505851]
[10]
Ball FR. Federal pre-emption under the Food, Drug & Cosmetic Act from Medtronic, Inc. v. Lohr; Pliva. Inc. v. Mensing. Health care law monthly. 2011 Sep:2011(9):2-8
[PubMed PMID: 21949984]
[11]
Svynarenko R, Mack JW, Lindley LC. Differences in characteristics of children with cancer who receive standard versus concurrent hospice care. Pediatric blood & cancer. 2021 Sep:68(9):e29106. doi: 10.1002/pbc.29106. Epub 2021 May 27
[PubMed PMID: 34047060]
[12]
Caswell-Jin JL, Callahan A, Purington N, Han SS, Itakura H, John EM, Blayney DW, Sledge GW Jr, Shah NH, Kurian AW. Treatment and Monitoring Variability in US Metastatic Breast Cancer Care. JCO clinical cancer informatics. 2021 May:5():600-614. doi: 10.1200/CCI.21.00031. Epub
[PubMed PMID: 34043432]
[13]
Bouchard ME, Kwon S, Many BT, Vacek JC, Abdullah F, Ghomrawi H. Impact of the Affordable Care Act's Medicaid expansion on tertiary pediatric surgical care. Journal of pediatric surgery. 2022 Mar:57(3):502-508. doi: 10.1016/j.jpedsurg.2021.04.012. Epub 2021 Apr 28
[PubMed PMID: 34034883]
[14]
Nasr A, Lauterio TJ, Davis MW. Unapproved drugs in the United States and the Food and Drug Administration. Advances in therapy. 2011 Oct:28(10):842-56. doi: 10.1007/s12325-011-0059-4. Epub 2011 Sep 1
[PubMed PMID: 21894470]
Level 3 (low-level) evidence
[15]
Yang LP. Oral colchicine (Colcrys): in the treatment and prophylaxis of gout. Drugs. 2010 Aug 20:70(12):1603-13. doi: 10.2165/11205470-000000000-00000. Epub
[PubMed PMID: 20687623]
[16]
Bonson KR. Regulation of human research with LSD in the United States (1949-1987). Psychopharmacology. 2018 Feb:235(2):591-604. doi: 10.1007/s00213-017-4777-4. Epub 2017 Nov 17
[PubMed PMID: 29147729]
[17]
Oketch-Rabah HA, Roe AL, Rider CV, Bonkovsky HL, Giancaspro GI, Navarro V, Paine MF, Betz JM, Marles RJ, Casper S, Gurley B, Jordan SA, He K, Kapoor MP, Rao TP, Sherker AH, Fontana RJ, Rossi S, Vuppalanchi R, Seeff LB, Stolz A, Ahmad J, Koh C, Serrano J, Low Dog T, Ko R. United States Pharmacopeia (USP) comprehensive review of the hepatotoxicity of green tea extracts. Toxicology reports. 2020:7():386-402. doi: 10.1016/j.toxrep.2020.02.008. Epub 2020 Feb 15
[PubMed PMID: 32140423]
[18]
Getz KA, Stergiopoulos S, Kaitin KI. Evaluating the completeness and accuracy of MedWatch data. American journal of therapeutics. 2014 Nov-Dec:21(6):442-6. doi: 10.1097/MJT.0b013e318262316f. Epub
[PubMed PMID: 23011177]
[19]
Lehrer S, Rheinstein PH, Rosenzweig KE. No Relationship of Anti-Androgens to Alzheimer's Disease or Cognitive Disorder in the MedWatch Database. Journal of Alzheimer's disease reports. 2018 Jun 30:2(1):123-127. doi: 10.3233/ADR-180052. Epub 2018 Jun 30
[PubMed PMID: 30480255]
[20]
Duprey MS, Al-Qadheeb NS, O'Donnell N, Hoffman KB, Weinstock J, Madias C, Dimbil M, Devlin JW. Serious Cardiovascular Adverse Events Reported with Intravenous Sedatives: A Retrospective Analysis of the MedWatch Adverse Event Reporting System. Drugs - real world outcomes. 2019 Sep:6(3):141-149. doi: 10.1007/s40801-019-00161-y. Epub
[PubMed PMID: 31399842]
Level 2 (mid-level) evidence
[21]
Miller JE, Korn D, Ross JS. Clinical trial registration, reporting, publication and FDAAA compliance: a cross-sectional analysis and ranking of new drugs approved by the FDA in 2012. BMJ open. 2015 Nov 12:5(11):e009758. doi: 10.1136/bmjopen-2015-009758. Epub 2015 Nov 12
[PubMed PMID: 26563214]
Level 2 (mid-level) evidence
[22]
Zou CX, Becker JE, Phillips AT, Garritano JM, Krumholz HM, Miller JE, Ross JS. Registration, results reporting, and publication bias of clinical trials supporting FDA approval of neuropsychiatric drugs before and after FDAAA: a retrospective cohort study. Trials. 2018 Oct 23:19(1):581. doi: 10.1186/s13063-018-2957-0. Epub 2018 Oct 23
[PubMed PMID: 30352601]
Level 2 (mid-level) evidence
[23]
Talebi R, Redberg RF, Ross JS. Consistency of trial reporting between ClinicalTrials.gov and corresponding publications: one decade after FDAAA. Trials. 2020 Jul 23:21(1):675. doi: 10.1186/s13063-020-04603-9. Epub 2020 Jul 23
[PubMed PMID: 32703252]
[24]
Phillips AT, Desai NR, Krumholz HM, Zou CX, Miller JE, Ross JS. Association of the FDA Amendment Act with trial registration, publication, and outcome reporting. Trials. 2017 Jul 18:18(1):333. doi: 10.1186/s13063-017-2068-3. Epub 2017 Jul 18
[PubMed PMID: 28720112]
[25]
Morrato EH, Ling SB. The Drug Safety and Risk Management Advisory Committee: a case study of meeting frequency, content, and outcomes before and after FDAAA. Medical care. 2012 Nov:50(11):970-86. doi: 10.1097/MLR.0b013e31826c872d. Epub
[PubMed PMID: 23047787]
Level 3 (low-level) evidence
[26]
Yeung KS, Gubili J, Mao JJ. Herb-Drug Interactions in Cancer Care. Oncology (Williston Park, N.Y.). 2018 Oct 15:32(10):516-20
[PubMed PMID: 30334243]
[27]
Allyse MA, Robinson DH, Ferber MJ, Sharp RR. Direct-to-Consumer Testing 2.0: Emerging Models of Direct-to-Consumer Genetic Testing. Mayo Clinic proceedings. 2018 Jan:93(1):113-120. doi: 10.1016/j.mayocp.2017.11.001. Epub
[PubMed PMID: 29304915]
[28]
Isbell TS. Direct-to-Consumer Tests on the Market Today: Identifying Valuable Tests from Those with Limited Utility. Clinics in laboratory medicine. 2020 Mar:40(1):13-23. doi: 10.1016/j.cll.2019.11.008. Epub
[PubMed PMID: 32008636]
[29]
Okuda BC, Tabbaa S, Edmonds M, Toubouti Y, Saltaji H. Direct to consumer orthodontics: Exploring patient demographic trends and preferences. American journal of orthodontics and dentofacial orthopedics : official publication of the American Association of Orthodontists, its constituent societies, and the American Board of Orthodontics. 2021 Feb:159(2):210-216.e2. doi: 10.1016/j.ajodo.2019.12.024. Epub 2020 Dec 18
[PubMed PMID: 33342673]
[30]
Christiansen CW, Gerdes AA. [Advantages and disadvantages of direct-to-consumer genetic tests]. Ugeskrift for laeger. 2017 Mar 13:179(11):. pii: V12160896. Epub
[PubMed PMID: 28330535]